Royalty Pharma plc
RPRX
$39.67
$0.140.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.02% | -70.42% | 4,888.47% | -57.88% | 654.34% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 14.77% | 16.36% | 21.43% | 9.61% | 6.73% |
| Total Other Non-Cash Items | 31.38% | -167.62% | -588.68% | 42.51% | -255.02% |
| Change in Net Operating Assets | 7.58% | 7.89% | 6.96% | 4.24% | 15.25% |
| Cash from Operations | -0.14% | -44.70% | -10.32% | -3.90% | 22.68% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 19.67% | 73.38% | 681.55% | 49.45% | -164.66% |
| Cash from Investing | 19.65% | 65.07% | 681.55% | 49.45% | -164.66% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -50.95% | -264.47% | -- | -74.20% | 30.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.33% | 1.79% | -1.65% | -4.83% | -4.80% |
| Other Financing Activities | -11.56% | 11.94% | -16.05% | 0.58% | -3.68% |
| Cash from Financing | 272.88% | -143.91% | -344.01% | -11.24% | 76.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 137.69% | -149.46% | -56.64% | 95.42% | 34.13% |